Proinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic class

References

• Piane M, Lulli P, Farinelli I et al. Genetics of migraine and pharmacogenomics: some considerations. J. Headache Pain8(9), 334–339 (2007).
   PubMedGoogle Scholar
• Montagna P. The primary headaches: genetics, epigegenetics and behavoural genetic model. J. Headache Pain9(2), 57–69 (2008).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Brøsen K. Pharmacoeconomics and migraine:possible implications. J. Headache Pain9(1), 13–18 (2008).
   PubMed Web of Science ®Google Scholar
• Martelletti P, Steiner TJ, Bertolote JM, Dua T, Saraceno B. The definitive position of headache among the major public health challenges. An end to the slippery slope of disregard. J. Headache Pain8(3), 149–151 (2007).
   PubMedGoogle Scholar
• Breslau N, Rasmussen BK. The impact of migraine: Epidemiology, risk factors, and co-morbidities. Neurology56(Suppl. 1), 4–12 (2001).
   PubMedGoogle Scholar
• Giniatullin R, Nistri A, Fabbretti E. Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF. Mol. Neurobiol.37(1), 83–90 (2008).
   PubMed Web of Science ®Google Scholar
• Xiao Y, Richter JA, Hurley JH. Release of glutamate and CGRP from trigeminal ganglion neurons: role of calcium channels and 5-HT1 receptor signaling. Mol. Pain16(4), 12 (2008).
   Google Scholar
• Durham PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache46(Suppl. 1), 3–8 (2006).
   PubMed Web of Science ®Google Scholar
• Blandini F, Rinaldi L, Tassorelli C et al. Peripheral levels of BDNF and NGF in primary headaches. Cephalalgia26(2), 136–142 (2006).
   PubMed Web of Science ®Google Scholar
• Sakai Y, Dobson C, Diksic M, Aubé M, Hamel E. Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. Neurology70(6), 431–439 (2008).
   PubMed Web of Science ®Google Scholar
• Bruno PP, Carpino F, Carpino G, Zicari A. An overview on immune system and migraine. Eur. Rev. Med. Pharmacol. Sci.11(4), 245–248 (2007).
   PubMed Web of Science ®Google Scholar
• Fidan I, Yüksel S, Ymir T, Irkeç C, Aksakal FN. The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J. Neuroimmunol.171(1–2), 184–188 (2006).
   PubMed Web of Science ®Google Scholar
• Rapoport AM. Acute treatment of headache. J. Headache Pain7(5), 355–359 (2006).
   PubMedGoogle Scholar
• Farinelli I, Martelletti P. Aspirin and tension-type headache. J. Headache Pain8(1), 49–55 (2007).
   PubMedGoogle Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol.231(25), 232–235 (1971).
   PubMedGoogle Scholar
• De Witt DL, El-Harith EA, Kraemer SA et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J. Biol. Chem.265(9), 5192–5198 (1990).
   PubMedGoogle Scholar
• Smith WL, De Witt DL. Prostaglandin endoperoxide H synthases 1 and -2. Adv. Immunol.62, 167–215 (1996).
   PubMed Web of Science ®Google Scholar
• Martelletti P, Farinelli I, Coloprisco G, Patacchioli FR. Role of NSAIDs in acute treatment of headache. Drug Dev. Res.68, 276–281(2007).
   Web of Science ®Google Scholar
• Schoenen J. When should triptans be taken during a migraine attack? CNS Drugs15(8), 583–587(2001).
   PubMed Web of Science ®Google Scholar
• Goldstein J, Silberstein S, Saper JR et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache45(8), 973–982(2005).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN. Aspirin is efficacious for the treatment of acute migraine. Headache45(4), 283–292(2005).
   PubMed Web of Science ®Google Scholar
• Pfaffenrath V, Scherzer S. Analgesics and NSAIDs in the treatment of the acute migraine attack. Cephalalgia15(Suppl. 15), 14–20(1995).
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Dowson A, Davies PT. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache42(4), 249–255 (2002).
   PubMed Web of Science ®Google Scholar
• Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared with subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia19(6), 581–588 (1999).
   PubMed Web of Science ®Google Scholar
• Codispoti JR, Prior MJ, Fu M, Harte CM, Nelson EB. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial. Headache41(7), 665–679 (2001).
   PubMed Web of Science ®Google Scholar
• Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac.potassium, in comparison to oral sumatriptan and placebo. Cephalalgia19(4), 232–240 (1999).
   PubMed Web of Science ®Google Scholar
• Smith TR, Sunshine A, Stuart RS, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache45(8), 983–991 (2005).
   PubMed Web of Science ®Google Scholar
• Saper J, Dahlof C, So Y et al. Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial. Headache46(2), 264–275 (2006).
   PubMedGoogle Scholar
• Von Seggern RL, Mannix LK, Adelman JU. Rofecoxib in the prevention of perimenstrual migraine: an open-label pilot trial. Headache44(2), 160–165 (2004).
   PubMed Web of Science ®Google Scholar
• Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA264(13), 1711–1713 (1990).
   PubMed Web of Science ®Google Scholar
• Hernández-Diaz S, García-Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med.4(20), 22 (2006).
   PubMed Web of Science ®Google Scholar
• Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke36(8), 1801–1807 (2005).
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Stenhubl SR, Berger PB et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am. J. Cardiol.95(10), 1218–1222 (2005).
   PubMed Web of Science ®Google Scholar
• Baldassarre S, Schandene L, Choufani G, Michils A. Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen. J. Allergy Clin. Immunol.117(1), 215–217 (2006).
   PubMed Web of Science ®Google Scholar
• Diener HC, Bussone G, de Liano H et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia24(11), 947–954 (2004).
   PubMed Web of Science ®Google Scholar
• Mathew NT. Transformed migraine. Cephalalgia13(Suppl. 12), 78–83 (1993).
   PubMedGoogle Scholar
• Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd Edition. Cephalalgia24(Suppl. 1), 9–160 (2004).
   PubMed Web of Science ®Google Scholar
• Saper JR, Hamel RL, Lake AE 3rd. Medication overuse headache (MOH) is a biobehavioural disorder. Cephalalgia25(7), 545–546 (2005).
   PubMed Web of Science ®Google Scholar
• Radat F, Creac’h C, Swendsen JD et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia25(7), 519–522 (2005).
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G. Rate and predictors for relapse in medication overuse headache: a one year prospective study. Neurology60(10), 1682–1684 (2003).
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Müssig M, Dzagnidze A, Frische G, Diener HC, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4 year prospective study. Cephalalgia25(1), 12–15 (2005).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs60(6), 1259–1287 (2000).
   PubMed Web of Science ®Google Scholar
• Chen LC, Ashcroft DM. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache48(2), 236–247 (2008).
   PubMedGoogle Scholar
• Adelman JU, Lipton RB, Ferrari MD et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology57(8), 1377–1383 (2001).
   PubMed Web of Science ®Google Scholar
• Misra UK, Kalita J, Yadav RK. Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial. J. Headache Pain8(3), 175–179 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia22(8), 633–658 (2002).
   Google Scholar
• Tfelt-Hansen P. Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment. J. Headache Pain8(5), 273–276 (2007).
   PubMedGoogle Scholar
• Panconesi A, Pavone E, Vacca F, Vaiani M, Banfi R. Triptans in the Italian population: a drug utilization study and a literature review. J. Headache Pain9(2), 71–76 (2008).
   PubMed Web of Science ®Google Scholar
• Dodick DW, Papademetriou V. Cardiovascular safety of triptans. Cephalalgia24(7), 513–514(2004).
   PubMed Web of Science ®Google Scholar
• Houghton LA, Foster J, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet344(8928), 985–986 (1994).
   PubMed Web of Science ®Google Scholar
• Boska MD, Welch KM, Schultz L, Nelson J. Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects. Cephalalgia20(1), 39–44 (2000).
   PubMed Web of Science ®Google Scholar
• MacLean MR, Clayton RA, Templeton AG, Morecroft I. Evidence for 5-HT-1-like receptor-mediated vasoconstrictionin human pulmonary artery. Br. J. Pharmacol.119(2), 277–282(1996).
   PubMed Web of Science ®Google Scholar
• Sarkar S, Aziz Q, Woolf CJ, Hobson AR, Thompson DG. Contribution of central sensitization to the development of non-cardiac chest pain. Lancet356(9236), 1154–1159 (2000).
   PubMed Web of Science ®Google Scholar
• Goldstein JA, Massey KD, Kirby S et al. Effect of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia24(7), 515–521 (2004).
   PubMed Web of Science ®Google Scholar
• Messlinger K, Hanesch U, Kurosawa M, Pawlak M, Schmidt RF. Calcitonin gene related peptide released from dural nerve fibers mediates increase of meningeal blood flow in the rat. Can. J. Physiol. Pharmacol.73(7), 1020–1024 (1995).
   PubMedGoogle Scholar
• Sun RQ, Tu YJ, Lawand NB, Yan JY, Lin Q, Willis WD. Calcitonin gene-related peptide receptor activation produces PKA- and PKC-dependent mechanical hyperalgesia and central sensitization. J. Neurophysiol.92(5), 2859–2866 (2004).
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Sams A, Jansen-Olesen I et al. Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries. Eur. J. Pharmacol.415(1), 39–44 (2001).
   PubMed Web of Science ®Google Scholar
• Lennerz JK, Rühle V, Ceppa EP et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J. Comp. Neurol.507(3), 1277–1299 (2008).
   PubMed Web of Science ®Google Scholar
• Conner AC, Hay DL, Howitt SG et al. Interaction of calcitonin-gene-related peptide with its receptors. Biochem. Soc. Trans.30(4), 451–455 (2002).
   PubMed Web of Science ®Google Scholar
• Saetrum Opgaard O, de Vries R, Tom B, Edvinsson L, Saxena PR. Positive inotropy of calcitonin gene-related peptide and amylin on porcine isolated myocardium. Eur. J. Pharmacol.385(2–3), 147–154 (1999).
   PubMedGoogle Scholar
• Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J. Headache Pain9(1), 5–12 (2008).
   PubMed Web of Science ®Google Scholar
• Arulmani U, Maassenvandenbrink A, Villalón CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur. J. Pharmacol.500(1–3), 315–330 (2004).
   PubMed Web of Science ®Google Scholar
• Buzzi MG. Reading data in migraine acute treatment studies: from clinical trials to reviews and meta-analyses. J. Headache Pain7(3), 160–164 (2006).
   PubMedGoogle Scholar
• Ma W, Chabot JG, Powell KJ, Jhamandas K, Dickerson IM, Quirion R. Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems. Neuroscience120(3), 677–694 (2003).
   PubMed Web of Science ®Google Scholar
• Buzzi MG, Moskovitz MA. The pathophysiology of migraine: year 2005. J. Headache Pain6(3), 105–111 (2005).
   PubMedGoogle Scholar
• Geppetti P, Capone JG, Trevisani M, Nicoletti P, Zagli G, Tola MR. CGRP and migraine: neurogenic inflammation revisited. J. Headache Pain6(2), 61–70 (2005).
   PubMedGoogle Scholar
• Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache31(6), 365–371 (1991).
   PubMed Web of Science ®Google Scholar
• Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia22(1), 54–61 (2002).
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Goadsby PJ. Neuropeptides in migraine and cluster headache. Cephalalgia14(5), 320–327 (1994).
   PubMed Web of Science ®Google Scholar
• Limmroth V, Katsarava Z, Liedert B et al. An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. Pain92(1–2), 101–106 (2001).
   PubMedGoogle Scholar
• Diener HC, Limmroth V. Acute management of migraine: triptans and beyond. Curr. Opin. Neurol.12(3), 261–267 (1999).
   PubMed Web of Science ®Google Scholar
• Yun HY, Dawson VL, Dawson TM. Neurobiology of nitric oxide. Crit. Rev. Neurobiol.10(3–4), 291–316 (1996).
   PubMedGoogle Scholar
• Faraci F, Heistad D. Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol. Rev.78(1), 53–97 (1998).
   PubMed Web of Science ®Google Scholar
• Li J, Vause CV, Durham PL. Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res.1196, 22–32 (2008).
   PubMed Web of Science ®Google Scholar
• Thalakoti S, Patil VV, Damodaram S et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache47(7), 1008–1023 (2007).
   PubMed Web of Science ®Google Scholar
• Eberhardt M, Hoffmann T, Sauer SK, Messlinger K, Reeh PW, Fischer MJ. Calcitonin gene-related peptide release from intact isolated dorsal root and trigeminal ganglia. Neuropeptides42(3), 311–317 (2008).
   PubMed Web of Science ®Google Scholar
• Juhasz G, Zsombok T, Modos EA et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain106(3), 461–470 (2003).
   PubMed Web of Science ®Google Scholar
• Kruuse C, Frandsen E, Schifter S, Thomsen LL, Birk S, Olesen J. Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache. Cephalalgia24(7), 547–553 (2004).
   PubMedGoogle Scholar
• Eikermann-Haerter K, Kudo C, Moskowitz MA. Cortical spreading depression and estrogen. Headache47(Suppl. 2), 79–85 (2007).
   Google Scholar
• Shimizu T, Toriumi H, Sato H et al. Distribution and origin of TRPV1 receptor-containing nerve fibers in the dura mater of rat. Brain Res.1173, 84–91 (2007).
   PubMedGoogle Scholar
• Helliwell RJ, McLatchie LM, Clarke M, Winter J, Bevan S, McIntyre P. Capsaicin sensitivity is associated with the expression of the vanilloid (capsaicin) receptor (VR1) mRNA in adult rat sensory ganglia. Neurosci. Lett.250(3), 177–180 (1998).
   PubMed Web of Science ®Google Scholar
• Murata Y, Masuko S. Peripheral and central distribution of TRPV1, substance P and CGRP of rat corneal neurons. Brain Res.1085(1), 87–94 (2006).
   PubMed Web of Science ®Google Scholar
• Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br. J. Pharmacol.142(7), 1171–1181 (2004).
   PubMed Web of Science ®Google Scholar
• Nicoletti P, Trevisani M, Manconi M et al. Ethanol causes neurogenic vasodilation by TRPV1 activation and CGRP release in the trigeminovascular system of the guinea pig. Cephalalgia28(1), 9–17 (2008).
   PubMed Web of Science ®Google Scholar
• Rudolf K, Eberlein W, Engel W et al. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. J. Med. Chem.48(19), 5921–5931 (2005).
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Alm R, Shaw D et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur. J. Pharmacol.434(1–2), 49–53 (2002).
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med.350(11), 1104–1110 (2004).
   PubMed Web of Science ®Google Scholar
• Salvatore CA, Hershey JC, Corcoran HA et al. Pharmacological characterization of TELCAGEPANT[N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J. Pharmacol. Exp. Ther.324(2), 416–421 (2008).
   PubMed Web of Science ®Google Scholar
• Paone DV, Shaw AW, Nguyen DN et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). J. Med. Chem.50(23), 5564–5567 (2007).
   PubMed Web of Science ®Google Scholar
• Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol. Sci.28(11), 580–587 (2007).
   PubMedGoogle Scholar
• Ho TW, Mannix LK, Fan X et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology70(16), 1304–1312 (2008).
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Paemeleire K, Jensen R et al. European Headache Federation; lifting the burden: the global campaign to reduce the burden of headache worldwide; World Health Organization. European principles of management of common headache disorders in primary care. J. Headache Pain8(Suppl. 1), 3–47 (2008).
   Google Scholar